As of March 2024, five CART-cell therapies had been approved for marketing in China, including Yescarta introduced by Fosun Kite from Gilead Sciences, Inc., Ruiqioren by Innovent Biologics, Inc., Ikioren by Innovent Biologics/Reindeer Healthcare, Nakioren by Heyuan Biology and Zewokioren by Coherus Pharmaceuticals. Other major Chinese domestic firms making progress are Gracell Biotechnology (Shanghai) Co., Ltd., and Nanjing Legend Biotechnology Co., Ltd.
The average selling price of therapies is around CNY1.16 million per dose ($160,220/dose), which is CNY840,000 yuan/dose lower than the global average selling price. Among them, the number of domestic products approved is far ahead, accounting for 80%
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?